Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)…
Ransomware Threats Expose Critical Infrastructure Gaps, Endangering Patient Safety in Key Nations MELBOURNE, AUSTRALIA / ACCESSWIRE / December 9, 2024…
Clinician-trained AI analyzes electronic records to match ideal patients with studies in seconds rather than hours, optimizing research and reducing…
Artist-Curated Playlists and Psychedelic Education Come Together to Inspire Safe, Intentional ExplorationWASHINGTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary…
Strong Eversense® 365 early launch indicators illustrated by largest number of new patient shipments and largest number of prescribing providers…
ANNOUNCEMENT NO. 287 9 December 2024 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to…
ANNOUNCEMENT NO. 286 9 December 2024 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30…
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in…
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell…
DELRAY BEACH, Fla., Dec. 6, 2024 /PRNewswire/ -- The global Data Protection as a Service Market will grow to USD…